← Back to headlines
Immunic Secures $400M for Late-Stage MS Trials
Immunic, a biopharmaceutical company, has successfully secured $400 million in funding to advance its late-stage clinical trials for Multiple Sclerosis (MS) treatments.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
